Genmab A/S (NASDAQ:GMAB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a note issued to investors on Tuesday, MarketBeat Ratings reports.
Other equities analysts have also issued reports about the company. Truist Financial increased their price objective on Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Tuesday. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. Finally, BTIG Research raised their price target on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Hold” and an average target price of $49.50.
View Our Latest Report on Genmab A/S
Genmab A/S Trading Up 1.1 %
Institutional Investors Weigh In On Genmab A/S
Several institutional investors and hedge funds have recently bought and sold shares of GMAB. Point72 Asset Management L.P. purchased a new position in shares of Genmab A/S in the 2nd quarter valued at approximately $457,000. Cubist Systematic Strategies LLC increased its holdings in shares of Genmab A/S by 109.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after acquiring an additional 478 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after acquiring an additional 45,376 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
- Five stocks we like better than Genmab A/S
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Energy and Oil Stocks Explained
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- 3 Best Fintech Stocks for a Portfolio Boost
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.